دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The growing role of artificial intelligence and of wearable devices in the management of arrhythmias
Filippo Crea
doi : 10.1093/eurheartj/ehab711
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3889–3893
A new initiative of the European Heart Journal: the Desmond Julian Award
Filippo Crea, Eugene Braunwald
doi : 10.1093/eurheartj/ehab535
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3894–3895
The 2020 Olympic/Paralympic Games and Covid-19 in Japan
Hiroaki Shimokawa
doi : 10.1093/eurheartj/ehab543
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3895–3896
Can the US COVID-19 Response Advance Equity in Cardiovascular Health?
Erica S Spatz, Adam L Beckman, Oyere K Onuma, Elias Mossialos
doi : 10.1093/eurheartj/ehab486
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3897–3899
Heart failure with preserved ejection fraction: a stepchild no more!
Eugene Braunwald
doi : 10.1093/eurheartj/ehab601
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3900–3901
A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetes
Massimo Volpe, Carlo Patrono
doi : 10.1093/eurheartj/ehab550
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3902–3903
Artificial intelligence in the diagnosis and management of arrhythmias
Venkat D Nagarajan, Su-Lin Lee, Jan-Lukas Robertus, Christoph A Nienaber, Natalia A Trayanova, Sabine Ernst
doi : 10.1093/eurheartj/ehab544
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3904–3916
The field of cardiac electrophysiology (EP) had adopted simple artificial intelligence (AI) methodologies for decades. Recent renewed interest in deep learning techniques has opened new frontiers in electrocardiography analysis including signature identification of diseased states. Artificial intelligence advances coupled with simultaneous rapid growth in computational power, sensor technology, and availability of web-based platforms have seen the rapid growth of AI-aided applications and big data research. Changing lifestyles with an expansion of the concept of internet of things and advancements in telecommunication technology have opened doors to population-based detection of atrial fibrillation in ways, which were previously unimaginable. Artificial intelligence-aided advances in 3D cardiac imaging heralded the concept of virtual hearts and the simulation of cardiac arrhythmias. Robotics, completely non-invasive ablation therapy, and the concept of extended realities show promise to revolutionize the future of EP. In this review, we discuss the impact of AI and recent technological advances in all aspects of arrhythmia care.
Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study
Joe-Elie Salem, Lee S Nguyen, Javid J Moslehi, Stéphane Ederhy, Bénédicte Lebrun-Vignes, Dan M Roden, Christian Funck-Brentano, Paul Gougis
doi : 10.1093/eurheartj/ehab362
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3915–3928
With the explosion of anticancer drugs, an emerging concern is the risk for drug-induced sudden death (SD) via ventricular arrhythmias (VA).
QT prolongation and cancer therapeutics: a coming Tempest or Much Ado About Nothing?
Lohit Garg, Michael G Fradley
doi : 10.1093/eurheartj/ehab483
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3929–3931
Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy
Victor Nauffal, Peter Marstrand, Larry Han, Victoria N Parikh, Adam S Helms, Jodie Ingles, Daniel Jacoby, Neal K Lakdawala, Sunil Kapur, Michelle Michels, Anjali T Owens, Euan A Ashley, Alexandre C Pereira, Joseph W Rossano, Sara Saberi, Christopher Semsarian, James S Ware, Samuel G Wittekind, Sharlene Day, Iacopo Olivotto, Carolyn Y Ho
doi : 10.1093/eurheartj/ehab598
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3932–3944
Risk stratification algorithms for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM) and regional differences in clinical practice have evolved over time. We sought to compare primary prevention implantable cardioverter defibrillator (ICD) implantation rates and associated clinical outcomes in US vs. non-US tertiary HCM centres within the international Sarcomeric Human Cardiomyopathy Registry.
Sudden cardiac death in hypertrophic cardiomyopathy: time to change the narrative
Perry Elliott
doi : 10.1093/eurheartj/ehab608
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3945–3947
Deep learning analysis of electrocardiogram for risk prediction of drug-induced arrhythmias and diagnosis of long QT syndrome
Edi Prifti, Ahmad Fall, Giovanni Davogustto, Alfredo Pulini, Isabelle Denjoy, Christian Funck-Brentano, Yasmin Khan, Alexandre Durand-Salmon, Fabio Badilini, Quinn S Wells, Antoine Leenhardt, Jean-Daniel Zucker, Dan M Roden, Fabrice Extramiana, Joe-Elie Salem
doi : 10.1093/eurheartj/ehab588
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3948–3961
Congenital long-QT syndromes (cLQTS) or drug-induced long-QT syndromes (diLQTS) can cause torsade de pointes (TdP), a life-threatening ventricular arrhythmia. The current strategy for the identification of drugs at the high risk of TdP relies on measuring the QT interval corrected for heart rate (QTc) on the electrocardiogram (ECG). However, QTc has a low positive predictive value.
Long QT syndrome, artificial intelligence, and common sense
Peter J Schwartz, Hanno L Tan
doi : 10.1093/eurheartj/ehab611
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3962–3964
Polymorphic ventricular tachycardia, ischaemic ventricular fibrillation, and torsade de pointes: importance of the QT and the coupling interval in the differential diagnosis
Raphael Rosso, Aviram Hochstadt, Dana Viskin, Ehud Chorin, Arie Lorin Schwartz, Oholi Tovia-Brodie, Avishag Laish-Farkash, Ofer Havakuk, Lior Gepstein, Shmuel Banai, Sami Viskin
doi : 10.1093/eurheartj/ehab138
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3965–3975
Distinctive types of polymorphic ventricular tachycardia (VT) respond differently to different forms of therapy. We therefore performed the present study to define the electrocardiographic characteristics of different forms of polymorphic VT.
Initiation and management of polymorphic ventricular tachycardia: history gone full circle
Christian van der Werf, Pier D Lambiase
doi : 10.1093/eurheartj/ehab428
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3976–3978
Day-to-day measurement of physical activity and risk of atrial fibrillation
Mathias Pinto Bonnesen, Diana My Frodi, Ketil Jørgen Haugan, Christian Kronborg, Claus Graff, Søren Højberg, Lars Køber, Derk Krieger, Axel Brandes, Jesper Hastrup Svendsen, Søren Zöga Diederichsen
doi : 10.1093/eurheartj/ehab597
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3979–3988
The aim of this study was to investigate the association between within-individual changes in physical activity and onset of atrial fibrillation (AF).
The ins and outs of physical activity monitoring: implications for atrial fibrillation management
Adrian D Elliott, Melissa E Middeldorp, Dominik K Linz
doi : 10.1093/eurheartj/ehab520
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3989–3991
Quinidine vs. ICD in patients with short-coupled idiopathic ventricular fibrillation: a call for a multicenter randomized trial
Bernard Belhassen
doi : 10.1093/eurheartj/ehab549
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Page 3992
Quinidine vs. ICD therapy in short-coupled ventricular fibrillation—is a randomized trial the next logical step?
Christian Steinberg, Andrew D Krahn
doi : 10.1093/eurheartj/ehab614
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Pages 3993–3994
Dysphagia aortica associated with dogleg descending thoracic aorta
Takuya Taniguchi, Kenji Nobuhara
doi : 10.1093/eurheartj/ehab125
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Page 3994
Platypnea–orthodeoxia syndrome: comprehensive analysis by multimodal imaging
Laetitia Neuvillers, Alaa Masri, Aurélie Veugeois, Christelle Diakov, Jean-François Paul
doi : 10.1093/eurheartj/ehab114
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Page 3995
Corrigendum to: The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl
doi : 10.1093/eurheartj/ehab351
European Heart Journal, Volume 42, Issue 38, 7 October 2021, Page 3991
